Brind.

FUCASO CAR-T Therapy Receives HSA Approval and Commercial Launch in Singapore

2 reports, 1 independent Updated Wed 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

IASO Bio and Pills and Pokes jointly hosted the commercial launch of FUCASO in Singapore on November 3, 2026. FUCASO is a fully human BCMA-targeted CAR-T cell therapy. Singapore's Health Sciences Authority approved the drug in June 2026 for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who progressed after at least three prior lines of therapy.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The approval marks the official commercialization of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. This expands the available treatment options for adult patients suffering from relapsed or refractory multiple myeloma.

From prnewswire.com

Who's involved

  • Health Sciences AuthoritySingapore's Health Sciences Authority, which approved the drug for R/R MM treatment.
  • NanjingLocation mentioned in the press release dateline.
  • PleasantonLocation mentioned in the press release dateline.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story